CIMG Inc. Faces Nasdaq Non-Compliance Notification Over Untimely Reporting

Notification of Non-Compliance from Nasdaq

CIMG Inc., often referred to as CIMG, is a prominent player in the realm of digital health and sales development, leveraging technology and marketing strategies to elevate its partners' sales and overall commercial value. However, the company is currently facing a compliance challenge that could impact its operations moving forward.

On August 20, 2025, CIMG received a delinquency notification letter from the Listing Qualifications Staff of Nasdaq Stock Market LLC, signaling a deviation from compliance with the Nasdaq Listing Rule 5250(c)(1). This rule mandates that publicly traded companies file their necessary periodic financial reports with the Securities and Exchange Commission (SEC) in a timely manner. The specific issue for CIMG revolves around the delayed submission of its Quarterly Report on Form 10-Q for the quarter ending June 30, 2025.

The implication of this notification is clear: CIMG must promptly address this deficiency. The Listing Qualifications Staff has indicated that CIMG must submit the number of shares issued and outstanding at the closure of each quarter to maintain compliance with Nasdaq's regulations. Additionally, the company is required to provide further details regarding this deficiency to the Nasdaq Hearings Panel by August 27, 2025. Thankfully, this notification does not presently affect the listing status or trading of CIMG's common stock on The Nasdaq Capital Market, which means investors need not panic for the moment.

Despite this setback, CIMG is determined to rectify the situation and has announced plans to file its overdue Form 10-Q as soon as possible. “Timely financial reporting is crucial not just for compliance but for maintaining investor confidence and ensuring transparency,” said a spokesperson from the company.

CIMG's initiatives extend beyond compliance, as the company stands committed to enhancing its business framework. Established as a global brand specializing in digital health and sales development, CIMG harnesses technology and effective marketing—including MarTech and Multi-Channel Networks—to drive sales growth for its partners. With an impressive portfolio featuring brands like Kangduoyuan, Maca-Noni, Qianmao, Huomao, and Coco-mango, CIMG is well-equipped to leverage its resources towards resolving the current compliance issue and continuing its growth trajectory.

In addition to the immediate requisite tasks, CIMG is also focusing on long-term strategies that could bolster its compliance systems and reporting efficiency. The company recognizes the importance of maintaining compliance not only to satisfy regulatory requirements but also as a foundational pillar for future investments and business expansions.

Looking ahead, CIMG understands that fostering a robust relationship with its stakeholders, including investors and regulatory bodies, will be essential to navigate through this period. The management plans to utilize this experience as a learning opportunity to improve its operational protocols and reporting practices.

While the company is faced with some hurdles, it is taking proactive steps to ensure that its future reporting aligns with all necessary regulations laid forth by Nasdaq and the SEC. The commitment to transparency and compliance is evident in CIMG's communications, where it emphasizes accountability and diligence in addressing the current issues.

In conclusion, although CIMG Inc. is currently managing a significant compliance challenge, the company's strategies to rectify the situation, combined with its inherent strengths in the marketplace, provide a solid foundation for managing investor expectations and assuring continuous growth in the digital health sector. The coming weeks will be critical as CIMG works to resolve its compliance status and reaffirms its commitment to transparency and stakeholder engagement.